1159 related articles for article (PubMed ID: 8752618)
21. Further studies on pituitary and ovarian function in women receiving hormonal contraception.
Cohen BL; Katz M
Contraception; 1981 Aug; 24(2):159-72. PubMed ID: 6794980
[TBL] [Abstract][Full Text] [Related]
22. Pulsatile luteinizing hormone secretion during the first and the fourth cycle on two different oral contraceptives containing gestodene.
Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
Acta Endocrinol (Copenh); 1993 Sep; 129(3):229-36. PubMed ID: 8212988
[TBL] [Abstract][Full Text] [Related]
23. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
Ruchhoft EA; Elkind-Hirsch KE; Malinak R
Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
[TBL] [Abstract][Full Text] [Related]
24. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
London RS; Chapdelaine A; Upmalis D; Olson W; Smith J
Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
[TBL] [Abstract][Full Text] [Related]
25. Comparison of contraceptive acceptability of levonorgestrel and ethinyl oestradiol administered in one three-phasic (Trionetta) and one monophasic (Neovletta) version.
Carlborg L
Contraception; 1983 May; 27(5):439-52. PubMed ID: 6349925
[TBL] [Abstract][Full Text] [Related]
26. Ovarian function during low-dose oral contraceptive use.
Egarter C; Putz M; Strohmer H; Speiser P; Wenzl R; Huber J
Contraception; 1995 Jun; 51(6):329-33. PubMed ID: 7554971
[TBL] [Abstract][Full Text] [Related]
27. Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment.
Elomaa K; Lähteenmäki P
Contraception; 1999 Nov; 60(5):275-9. PubMed ID: 10717779
[TBL] [Abstract][Full Text] [Related]
28. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles.
Landgren BM; Diczfalusy E
Contraception; 1984 May; 29(5):437-46. PubMed ID: 6430642
[TBL] [Abstract][Full Text] [Related]
29. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
Akerlund M; Røde A; Westergaard J
Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
[TBL] [Abstract][Full Text] [Related]
30. Influence of low dose oestrogen on circulating prolactin. LH and FSH levels in post-menopausal women.
Robyn C; Vekemans M
Acta Endocrinol (Copenh); 1976 Sep; 83(1):9-14. PubMed ID: 989226
[TBL] [Abstract][Full Text] [Related]
31. Temporary increase of FSH levels in healthy, nulliparous, young women after cessation of low-dose oral contraceptive use.
Jernstrom H; Knutsson M; Olsson H
Contraception; 1995 Jul; 52(1):51-6. PubMed ID: 8521715
[TBL] [Abstract][Full Text] [Related]
32. Ovarian activity during regular oral contraceptive use.
Crosignani PG; Testa G; Vegetti W; Parazzini F
Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
Lucky AW; Henderson TA; Olson WH; Robisch DM; Lebwohl M; Swinyer LJ
J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
[TBL] [Abstract][Full Text] [Related]
34. Effect of four combined oral contraceptives on blood pressure in the pill-free interval.
Nichols M; Robinson G; Bounds W; Newman B; Guillebaud J
Contraception; 1993 Apr; 47(4):367-76. PubMed ID: 8508666
[TBL] [Abstract][Full Text] [Related]
35. Dimeric inhibin serum values as markers of ovarian activity in pill-free intervals.
Renier MA; Vereecken A; Van Herck E; Straetmans D; Ramaekers P; Vanderheyden J; Degezelle H; Buytaert P
Contraception; 1998 Jan; 57(1):45-8. PubMed ID: 9554250
[TBL] [Abstract][Full Text] [Related]
36. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives.
Porcile A; Gallardo E
Fertil Steril; 1991 May; 55(5):877-81. PubMed ID: 1827074
[TBL] [Abstract][Full Text] [Related]
37. The effects of levonorgestrel, desogestrel and gestodene on the pulsatile release of luteinizing hormone in oral contraceptive users.
Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
Gynecol Endocrinol; 1993 Sep; 7(3):191-200. PubMed ID: 8291457
[TBL] [Abstract][Full Text] [Related]
38. When is it safe to switch from oral contraceptives to hormonal replacement therapy?
Castracane VD; Gimpel T; Goldzieher JW
Contraception; 1995 Dec; 52(6):371-6. PubMed ID: 8749601
[TBL] [Abstract][Full Text] [Related]
39. FSH and ovarian response: spontaneous recovery of pituitary-ovarian activity during the pill-free period vs. exogenous recombinant FSH during high-dose combined oral contraceptives.
van Heusden AM; Coelingh Bennink HJ; Fauser BC
Clin Endocrinol (Oxf); 2002 Apr; 56(4):509-17. PubMed ID: 11966744
[TBL] [Abstract][Full Text] [Related]
40. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel.
Gaspard UJ; Dubois M; Gillain D; Franchimont P; Duvivier J
Contraception; 1984 Apr; 29(4):305-18. PubMed ID: 6430638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
